{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:32:36Z","timestamp":1778542356040,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the characteristics of the COVID-19 infection course as well as preliminary safety and efficacy of Gam-COVID-Vac vaccine in patients with active GU malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were retrospectively identified at nine cancer centers in different regions. Patients were included if COVID-19 was diagnosed by a polymerase chain reaction. Data from additional patients with GU cancers who had no positive SARS-CoV-2 RT-PCR test before vaccination and who received two doses of Gam-COVID-Vac (Sputnik V) between 11 February and 31 August 2021 were collected for safety assessment. Anonymized data were collected through an online registry covering demographics, treatments, and outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The Gam-COVID-Vac vaccine was well tolerated; no grade 3\u20135 toxicities were reported in 112 vaccinated metastatic GU cancer patients. The most common grade 1 adverse events (81%) were injection site reactions (76%), flu-like illness (68%), and asthenia (49%). Five patients experienced grade 2 chills (4.5%) and 3 patients had grade 2 fever (2.7%). With median follow-up of 6.2\u00a0months, two COVID-19 cases were confirmed by RT-PCR test in the vaccine group (of 112 participants; 1.8%). Eighty-eight patients with COVID-19 disease were included in the analysis. The average age as of the study enrollment was 66 (range 39\u201381) and the majority of patients were male with renal cell carcinoma (RCC). Thirty-six patients (41%) had evidence of metastatic disease, of these 22 patients were receiving systemic therapy. More than half of patients required hospitalization. Fifty-four patients (61%) experienced complications. Sixteen patients who developed COVID-19 pneumonia required mechanical ventilator support. Sixteen patients (18%) died in a median of 23.5\u00a0days after the date of COVID-19 diagnosis was established. The 3-month survival rate was 82%. Clinical and\/or radiographic progression of cancer during COVID-19 infection or the subsequent 3\u00a0months was observed in 10 patients (11.4%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with GU malignancies are at increased risk of mortality from COVID-19 infection when compared to the general population. Vaccination could be safe in GU cancer patients.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-021-01205-z","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T11:02:37Z","timestamp":1636801357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-0392","authenticated-orcid":false,"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Volkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Alekseeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Berkut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Nosov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Myslevtsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Andrianov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Borisov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruslan","family":"Zukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Goutnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Savchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Dengina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur","family":"Mitin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"1205_CR1","unstructured":"Website. Official information on coronavirus in Russia. https:\/\/coronavirus.jhu.edu\/region\/russia. Accsessed 20 Sept 2021."},{"key":"1205_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/GO.20.00225","volume":"6","author":"VG Giannakoulis","year":"2020","unstructured":"Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Glob Oncol. 2020;6:799\u2013808. https:\/\/doi.org\/10.1200\/GO.20.00225.","journal-title":"JCO Glob Oncol"},{"key":"1205_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33213","author":"Y Tian","year":"2020","unstructured":"Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. Int J Cancer. 2020. https:\/\/doi.org\/10.1002\/ijc.33213.","journal-title":"Int J Cancer"},{"key":"1205_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","volume":"94","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91\u20135. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.017.","journal-title":"Int J Infect Dis"},{"key":"1205_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14124","author":"AK Singh","year":"2020","unstructured":"Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14124.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1205_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(20)30314-4.","journal-title":"Lancet Oncol"},{"issue":"18_suppl","key":"1205_CR7","doi-asserted-by":"publisher","first-page":"Abstract LBA110","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA110","volume":"38","author":"JL Warner","year":"2020","unstructured":"Warner JL, Rubinstein S, Grivas P, et al. Clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and cancer consortium (CCC19). J Clin Oncol. 2020;38(18_suppl):Abstract LBA110. https:\/\/doi.org\/10.1200\/JCO.2020.38.18_suppl.LBA110.","journal-title":"J Clin Oncol"},{"key":"1205_CR8","first-page":"1707","volume":"5","author":"I Tsimafeyeu","year":"2020","unstructured":"Tsimafeyeu I, Volkova M. Management of patients with renal cell carcinoma during coronavirus pandemic: proposed algorithm in Russia. Clin Oncol. 2020;5:1707.","journal-title":"Clin Oncol"},{"issue":"4","key":"1205_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.adro.2020.03.010","volume":"5","author":"NG Zaorsky","year":"2020","unstructured":"Zaorsky NG, Yu JB, McBride SM, et al. Prostate cancer radiation therapy recommendations in response to COVID-19. Adv Radiat Oncol. 2020;5(4):659\u201365. https:\/\/doi.org\/10.1016\/j.adro.2020.03.010.","journal-title":"Adv Radiat Oncol"},{"key":"1205_CR10","unstructured":"COVID-19 Resource: European Urology. https:\/\/www.europeanurology.com\/covid-19-resource. Accessed 04 Apr 2020"},{"issue":"3","key":"1205_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.23736\/S0393-2249.20.03846-1","volume":"72","author":"V Ficarra","year":"2020","unstructured":"Ficarra V, Novara G, Abrate A, et al. Research urology network (RUN). Urology practice during the COVID-19 pandemic. Minerva Urol Nefrol. 2020;72(3):369\u201375.","journal-title":"Minerva Urol Nefrol"},{"key":"1205_CR12","unstructured":"Coronavirus & COVID-19. The British Association of Urological Surgeons Limited. https:\/\/www.baus.org.uk\/about\/coronavirus_covid-19.aspx. Accessed 03 Apr 2020"},{"issue":"2","key":"1205_CR13","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.clgc.2020.07.007","volume":"19","author":"I Tsimafeyeu","year":"2021","unstructured":"Tsimafeyeu I, Alekseeva G, Berkut M, et al. COVID-19 in patients with renal cell carcinoma in the Russian Federation. Clin Genitourin Cancer. 2021;19(2):e69\u201371.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"1205_CR14","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s00432-020-03341-4","volume":"146","author":"P Ivanyi","year":"2020","unstructured":"Ivanyi P, Gr\u00fcllich C, Kroeger N, et al. Interdisciplinary working group on renal tumors (IAG-N) of the German Cancer Socity (DKG). Systemic treatment of advanced\/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). J Cancer Res Clin Oncol. 2020;146(11):3075\u20138. https:\/\/doi.org\/10.1007\/s00432-020-03341-4.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01205-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01205-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01205-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T23:06:37Z","timestamp":1636844797000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01205-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01205-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have stated that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}